Adjuvant Capital

Adjuvant Capital is a New York-based life sciences venture capital firm established in 2018. The firm specializes in financing clinical-stage medical technologies that address significant public health challenges, particularly in low- and middle-income countries. Adjuvant Capital aims to achieve strong financial returns while ensuring that innovations such as vaccines, therapeutics, and diagnostics are accessible to underserved populations. The firm primarily makes preferred equity investments in technologies that have demonstrated safety and efficacy in humans, with investment sizes typically ranging from $10 million to $25 million. Adjuvant Capital manages a $300 million venture fund and focuses on high-burden health categories, including infectious diseases, maternal and child health, reproductive health, and nutrition. Its notable portfolio includes companies like VitriVax and Codagenix, showcasing its commitment to impactful medical advancements.

Preferred equity investments in clinical-stage life science technologies for neglected and high-burden diseases, targeting both social impact and financial returns in underserved global health markets.